May 2022 in “Journal of Education, Health and Sport” Skin diseases like psoriasis, lupus, and others can increase heart disease risk due to factors like chronic inflammation and genetic susceptibility.
May 2022 in “Clinical Epigenetics” A mother's iron levels early in pregnancy can influence the DNA makeup of her child, potentially affecting the child's health.
November 2021 in “Research Outreach” Low testosterone levels may lead to more severe COVID-19 outcomes.
October 2020 in “Проблемы эндокринологии” Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.
6 citations,
September 2020 in “Journal of The American Academy of Dermatology” Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.
176 citations,
May 2020 in “Dermatologic Therapy” COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.
1 citations,
August 2021 in “Internal Medicine Journal” After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.
77 citations,
July 2020 in “European Journal of Clinical Pharmacology” Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.
58 citations,
December 2020 in “Mayo Clinic Proceedings” The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
32 citations,
July 2020 in “Journal of The American Academy of Dermatology” AGA linked to worse COVID-19 outcomes in men.
27 citations,
October 2020 in “Experimental Dermatology” Having a lot of gray hair and hair loss are linked to more severe COVID-19.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
15 citations,
August 2021 in “Reviews in endocrine and metabolic disorders” COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.
6 citations,
December 2020 in “Dermatological reviews” COVID-19 may worsen with androgens; anti-androgen drugs could help.
5 citations,
December 2021 in “Physiological Research” Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.
5 citations,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
25 citations,
January 2022 in “Endocrine journal” Long COVID patients may have hormonal imbalances linked to their symptoms.
12 citations,
October 2013 in “The Prostate” Dutasteride and finasteride affect different cell types differently.
7 citations,
December 2020 in “Clinics in Dermatology” Some alopecia treatments might help treat COVID-19, but more research is needed.
November 2020 in “Journal of The American Academy of Dermatology” Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.
January 2021 in “International Journal of Dermatology” Possible link between COVID-19 and hair loss; more research needed.
5 citations,
December 2021 in “Scientific Reports” Age affects how certain proteins involved in COVID-19 infection are expressed in mice, but sex hormones and heart injury do not.
5 citations,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
5 citations,
July 2022 in “Journal of Clinical Medicine” Long COVID-19 patients with skin pain might have a nerve condition that responds to a medication called gabapentin.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.